Biora Therapeutics, Inc. (NASDAQ:BIOR) Sees Large Drop in Short Interest

Biora Therapeutics, Inc. (NASDAQ:BIOR) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 140,800 shares, a decline of 93.4% from the September 30th total of 2,130,000 shares. Currently, 4.1% of the company’s shares are sold short. Based on an average daily volume of 30,500 shares, the short-interest ratio is presently 4.6 days.

Biora Therapeutics Trading Up 15.7 %

Shares of Biora Therapeutics stock traded up $0.55 during trading on Friday, reaching $4.05. The company’s stock had a trading volume of 125,692 shares, compared to its average volume of 34,589. The firm has a market cap of $14.90 million, a PE ratio of -0.07 and a beta of 1.22. Biora Therapeutics has a fifty-two week low of $3.38 and a fifty-two week high of $21.10. The company has a 50-day moving average price of $5.94 and a two-hundred day moving average price of $6.42.

Biora Therapeutics (NASDAQ:BIOR) last posted its quarterly earnings data on Monday, August 12th. The company reported ($3.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.50) by $1.00. The company had revenue of $0.32 million for the quarter. On average, analysts predict that Biora Therapeutics will post -12.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $150.00 price target on shares of Biora Therapeutics in a research note on Tuesday, August 13th.

Biora Therapeutics Company Profile

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.